Vardenafil



Vardenafil
Systematic (IUPAC) name
4-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonyl-phenyl]-
9-methyl-7-propyl- 3,5,6,8-tetrazabicyclo[4.3.0]
nona-3,7,9-trien-2-one
Identifiers
CAS number 224785-90-4
ATC code G04BE09
PubChem 110634
DrugBank APRD00699
Chemical data
S 
Mol. mass 488.604 g/mol
Pharmacokinetic data
Bioavailability 15%
Protein binding 95%
CYP3A4)
Half life 4–5 hours
Excretion Biliary
Therapeutic considerations
Pregnancy cat.

B3 (Au), B (U.S.)

Legal status

Prescription Only (S4)(AU) -only(US)

Routes Oral

Vardenafil (Bayer AG).

History

Vardenafil was co-marketed by GSK on Levitra have been "transferred back" to Bayer in many markets outside of the United States. In Italy, Bayer markets the product as Levitra and GSK markets the product as Vivanza. Due to European Union trade rules, parallel imports may result in the Vivanza branded packs being seen alongside Levitra packs in pharmacies in other EU member states.

Clinical use

Main article: PDE5 inhibitor

Indications and contraindications are as for other nitrogen atom in its structure. It has a relatively short effective time, comparable to sildenafil.

Adverse drug reactions

More common adverse drug reactions (ADRs) are as per other PDE5 inhibitors and are listed on that page.

Common vardenafil-specific ADRs include: nausea. Infrequent ADRs include: abdominal pain, back pain, photosensitivity, abnormal vision, eye pain, facial oedema, hypertension, palpitation, tachycardia, arthralgia, myalgia, rash, itch, priapism. (Rossi, 2004)

The use of products containing vardenafil has also been associated with serious side-effects which include serious cardiac events such as heart attacks. In rare cases, the use of vardenafil may result in penile tissue damage and permanent loss of potency. Health Canada (2006)

On October 18, 2007, the FDA announced that a warning about possible sudden hearing loss would be added to the drug labels of vardenafil and other PDE5 inhibitors.[1]

Drug interactions

Products containing vardenafil should not be used by individuals who are taking any nitrate medication because combining these products could result in the development of potentially life-threatening low blood pressure.

Dose forms

It is available in 2.5 mg, 5 mg, 10 mg, and 20 mg doses in round orange tablets. The normal starting dose is 10 mg (roughly equivalent to 50 mg of sildenafil). Vardenafil should be taken 25–60 minutes prior to sexual activity, with a maximum dose frequency of once per day. In some territories, such as the UK, only certain doses may be available, i.e. 5 mg, 10 mg, and 20 mg.

See also

Notes

  1. ^ FDA Announces Revisions to Labels for Cialis, Levitra and Viagra. Food and Drug Administration (2007-10-18). Retrieved on 2007-12-08.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vardenafil". A list of authors is available in Wikipedia.